FRBRX Franklin Biotechnology Discovery R6 Forecast, Technical & Fundamental Analysis

The most notable companies in this group are AstraZeneca PLC (NASDAQ:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Intra-Cellular Therapies (NASDAQ:ITCI).

The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. It is non-diversified.

The average market capitalization across the Franklin Biotechnology Discovery R6 MF is 83.3B. The market cap for tickers in the group ranges from 6.7B to 208.98B. AZN holds the highest valuation in this group at 208.98B. The lowest valued company is ITCI at 6.7B.

The average weekly volume growth across all stocks in the Franklin Biotechnology Discovery R6 MF was 37%. For the same stocks of the MF, the average monthly volume growth was -34% and the average quarterly volume growth was 42%